Recent U.S., Canadian, and British Regulatory Agency Actions Concerning Antidepressant-Induced Harm to Self and Others: A Review and Analysis

Breggin, Peter R.
March 2005
Ethical Human Psychology & Psychiatry;Spring2005, Vol. 7 Issue 1, p7
Academic Journal
Drug regulatory agencies in the United States, Great Britain, and Canada have recently issued warnings concerning the use of antidepressants. Considerable attention has been placed on regulatory agency conclusions that antidepressants are associated with increased rates of suicidality in children. In the United States (the FDA) and Canada (Health Canada), new warnings have also been issued for children and adults concerning the production of an activation or stimulant syndrome that is known to be associated with violence and suicide. Health Canada requires a warning that selective serotonin inhibitors (SSRls) and other newer antidepressants produce in children and adults "agitation-type adverse events coupled with self-harm or harm to other," including "akathisia (psychomotor restlessness), agitation, disinhibition, emotional lability, hostility, aggression, depersonalization." The FDA requires a warning that "The following symptoms; anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric." Recent studies confirm that antidepressants are associated with adverse events that can cause aggression, hostility, and violence, as well as suicidality, in both children and adults.


Related Articles

  • Public health advisory on antidepressant use in adults.  // Patient Care;Aug2005, Vol. 39 Issue 8, p8 

    Reports on a public health advisory issued by the U.S. Food and Drug Administration on the possible links between antidepressant use in adults and suicidal behavior. Increase in the risk of adult suicidal behavior when being treated with antidepressants according to scientific reports.

  • The Triumph Of Thorazine And Prozac.  // Health & Stress;2004, Issue 4, p3 

    Focuses on the success of Thorazine and Prozac in treating schizophrenia. Side effects of Thorazine; Development of tardive dyskinesia.

  • Kids and Depression. Lemonick, Michael D. // Time International (South Pacific Edition);6/21/2004, Issue 24, p67 

    The article presents information related to depression in children. One of the best tools for fighting depression is the so-called SSRI class of drugs, including Prozac, Paxil and Zoloft. But evidence has been mounting that these relatively safe medications might trigger suicidal thoughts in...

  • Second opinion.  // Mayo Clinic Health Letter;Jul2009, Vol. 27 Issue 7, p8 

    The article presents questions and answers related to the probability of withdrawal after quitting an antidepressant, and what precautionary measures can be taken for a heatstroke.

  • The dark side of psychiatric drugs. Bibeau, Tanya // USA Today Magazine;May94, Vol. 122 Issue 2588, p44 

    Features the extreme and deadly effects of psychiatric drugs. Tranquilizers as the most dangerous psychiatric drugs which create maximum behavioral disruption; History of the drugs' capability to cause insanity; Relationship of aggression and psychiatric drugs; Cases of extreme effects of Prozac...

  • Pilots on Prozac. Lopez, Ramon // Aviation Today's Daily Brief;4/8/2010, Vol. 2 Issue 66, p2 

    The article reports on the plan of the U.S. Federal Aviation Administration (FAA) to issue medical certificates to pilots taking medication for mild to moderate depression starting April 5, 2010. FAA will allow pilots taking fluoxetine, sertraline, citalopram or escitalopram if they were treated...

  • Nortriptyline superior to fluoxetine in first comparative trial for post-stroke depression.  // Formulary;May2000, Vol. 35 Issue 5, p453 

    Reports that tricyclic antidepressant nortriptyline appears to be superior to the selective serotonin reuptake inhibitor fluoxetine for treating post-stroke depression, according to Iowa researchers. Clinical tests results; Hamilton Rating Scale for Depression; Improvement in activities of...

  • Antidepressants.  // Mayo Clinic Health Letter;Jul1994, Vol. 12 Issue 7, p6 

    Presents an interview with Mayo Clinic psychiatrist Jeffrey D. Rome on antidepressants and mood-altering drugs. Ethical questions in their use; Selective serotonin re-uptake inhibitors; Prozac.

  • Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Dekeyne, Anne; Iob, Loretta; Millan, Mark J. // Psychopharmacology;2001, Vol. 153 Issue 3, p389 

    Abstract Rationale: The discriminative stimulus (DS) properties of the selective serotonin (5-HT) uptake inhibitor (SSRI), citalopram, are mediated by 5-HT[sub 2C] receptors. Interestingly, the "atypical" antidepressants, mianserin and mirtazapine, behave as antagonists' at 5-HT[sub 2C]...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics